We are a private Israeli based-biopharmaceutical company that specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients. Our products are designed to modulate and control the human immune system in order to direct the power of these natural defenses toward the treatment of cancer and infectious diseases.

Financial support from the Israel Office of the Chief Scientist, Trendlines and Hadasit

We were incorporated in May, 2004 when, after a competitive review process, the project won financial support from the Israel Office of the Chief Scientist. We were sponsored by Trendlines Medical (previously Misgav Venture Accelerator), a member of Israel’s famous technological incubator system and by Hadasit, the business arm of Hadassah-Hebrew University Medical Center in Jerusalem.

Over $25m raised to date

Since founding, we have been supported by private individual investors.  We now have over 200 individuals as part of the Immunovative shareholder family.  We have raised over US$25 million since founding. These funds have been carefully invested to create an emerging clinical stage biopharmaceutical company.  We do not outsource our critical functional areas. We have developed our own in-house infrastructure with capabilities for GMP manufacturing, immunological monitoring and in-house clinical research organization (CRO) and site management (SMO) services.  Our efficient operations and technology platform allow us to provide next generation products that are not only effective against disease, but are also cost effective to manufacture.  

Our goal: To find a cure for cancer and HIV in our lifetime

Our employees are our most precious and valuable asset.  The skills and dedication of our multi-disciplinary team have allowed us to advance much further, using much less money, than our competitors in the biopharmaceutical business. Our employee team and our family of shareholders are dedicated to improving the lives of patients that suffer from cancer and infectious diseases.  We are humbled by the power of the immune system to protect us from disease. We have dedicated our careers to understanding and harnessing the power of the immune system in order to replace toxic and minimally effective therapies with our gentle, powerful, cost effective, next generation immunotherapy products. Our success will not only benefit our patients and shareholders, but also society as a whole in terms of reducing healthcare costs and improving quality of life.  Control of the immune system can eventually lead to cures for cancer and infectious diseases.  Our goal is to find a cure for cancer and HIV in our lifetime.   

Creating a new medical industry

We are building an international biopharmaceutical company based in Israel which will export technology and products capable of improving the quality of life of patients all over the world suffering from devastating diseases. We envision not just creating an international biopharmaceutical company, but developing a company that will be the foundation of a new industry. Successfully learning how to control the immune system can create a new medical industry in the same manner that Microsoft software created a new personal computer industry.



Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals

Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more